Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
Category: #health  By Pankaj Singh  Date: 2019-08-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
  • Outputs from single ascending dose specify that TERN-201 is well tolerated and generally safe & can inhibit plasma SSAO activity.
     
  • This trial has now transitioned onto the next level; multiple-ascending dose phase.

Terns Pharmaceuticals, Inc., an international biopharmaceutical company aimed at developing and discovering innovative therapies to treat cancer and non-alcoholic steatohepatitis (NASH), reportedly announced interim outputs of, currently under progress, clinical trial of TERN-201, an inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), being made for NASH treatment.

Interim data of first clinical study of TERN-201 tells that single, oral TERN-201 administrations were well handled with no important safety findings or any adverse events experienced that would lead to discontinuation. Every dose level studied showed reduction from baseline in SSAO activity of plasma that was maintained up to a week after the single dose TERN-201 administration. Study has now transitioned to multiple dose phase based on these outputs.

Chief Medical Officer of Terns, Erin Quirk, M.D. stated that the data seen till date from the clinical study in Phase 1 of TERN-201 has been encouraging and showed that TERN-201 is capable of being a therapy to treat liver fibrosis and NASH. Terns has further advanced two compounds into clinical development this year with TERN-101, a FXR agonist, and Tern-201 in current studies.

Quirk added that the company looks forward to check further outcomes from Phase 1 studies of TERN-201 and TERN-101 in this year as the company progresses towards its goal of unveiling effective and safe combination treatments for NASH.

Initially, TERN-201 was developed and discovered by Eli Lilly & Company. Terns made a global exclusive deal with Eli Lilly last year to manufacture, develop and commercialize TERN-201 for treating NASH. In Vienna, at International Liver CongressTM 2019, Terns presented preclinical information expressing that TERN-201 enhances NAFLD Activity Score (NAS) & fibrosis in rodent subjects of NASH.

 

Credit Source:

https://www.ternspharma.com/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
By Pankaj Singh

Number of cases where people are affected with neurodegenerative diseases have been growing at a substantial pace. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases found across the world. Various ...

AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
By Pankaj Singh

Owing to widescale tobacco use, the world is seeing an increased number of cancer and vascular diseases. India alone registers more than 10 million cases of peripheral artery disease on an annual basis. Technology and healthcare enterprises are incre...

Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
By Pankaj Singh

SMA is a rare genetic disease that typically affects young children. Currently, there is no cure for spinal muscular atrophy (SMA), however, various pharmaceutical firms across the world are working to discover a novel, innovative treatment for the d...